BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
65.29
-0.32 (-0.49%)
At close: Aug 27, 2026, 4:00 PM EDT
64.00
-1.29 (-1.98%)
After-hours: Aug 27, 2026, 5:28 PM EDT

BioMarin Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
72.97348.9426.86167.65141.56-64.08
Depreciation & Amortization
145.5772.1696.43104.39101.97108.04
Other Amortization
7.47.4----
Loss (Gain) From Sale of Assets
---10--108-
Asset Writedown & Restructuring Costs
343.01345.9819.8938.61--
Loss (Gain) From Sale of Investments
-4.8-4.8-8.35-9.233.045.16
Stock-Based Compensation
215.33181.41201.57207.1196.31197.26
Other Operating Activities
138.05170.6162.84-12.71-62.6-7.88
Change in Accounts Receivable
-117.94-228.05-57.91-190.44-82.0365.57
Change in Inventory
-32.13-116.93-63.53-157.06-68.26-35.06
Change in Accounts Payable
89.2966.14-32.2468.8559.0215.69
Change in Other Net Operating Assets
0.33-14.81-62.72-57.9-5.119.83
Operating Cash Flow
857.09827.99572.84159.26175.9304.54
Operating Cash Flow Growth
11.78%44.54%259.69%-9.46%-42.24%256.75%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-118.91-103.04-85.42-96.69-120.96-95.58
Cash Acquisitions
-5,353-285.19----
Sale (Purchase) of Intangibles
-13.1-7.94-1.99-10.9292.74-23.65
Investment in Securities
730.11-18.07222.77-3.638.19-246.09
Other Investing Activities
4.97-1.14---0.99
Investing Cash Flow
-4,750-414.24136.49-111.24-20.03-366.31

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
---494.99---3.04
Net Debt Issued (Repaid)
3,650--494.99---3.04
Issuance of Common Stock
13.4114.4649.2869.3569.3349.19
Repurchase of Common Stock
-44.38-55.97-77.56-76.32-54.28-45.81
Other Financing Activities
-66.49-0.89-3.18-11.76-33.7-0.4
Financing Cash Flow
3,553-42.39-526.45-18.73-18.65-0.05

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.33-2.524.831.310.03-0.06
Net Cash Flow
-339.81368.84187.7230.6137.26-61.88

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
738.18724.96487.4262.5754.94208.96
Free Cash Flow Growth
6.23%48.73%679.02%13.88%-73.71%-
Free Cash Flow Margin
21.67%22.50%17.08%2.59%2.62%11.32%
Free Cash Flow Per Share
3.763.672.480.330.291.14
Levered Free Cash Flow
85.16402.66212.05-17.35137.32201.61
Unlevered Free Cash Flow
137.41409.47219.97-6.52147.3211.19

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
7.327.2510.3610.310.2810.4
Cash Income Tax Paid
87.3296.2157.2773.3154.3718.15
Change in Working Capital
-60.45-293.66-216.4-336.54-96.3866.03
SEC Filings: 10-K · 10-Q